SecurityFTK / Flotek Industries Inc. (343389102)
IndustryMiscellaneous Chemical Products
Common Shares Outstanding56,958,671 shares (as of 2018-06-30)
Total Insiders16
Total Directors10
Total Officers7

Stock Insider Trading (from SEC Form 4)

Flotek Industries Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

FTK / Flotek Industries Inc. insiders include SNIVELY JOSHUA A, Bodnar Robert C, Schmitz Robert M., Nierenberg David Hardy Carla S., REEVES STEVEN A, Marietta Matthew B, and Brown Ted D, REILAND JOHN, Cooper L Melvin, CHISHOLM JOHN, Adams Michelle M, Walton H. Richard, McGuire LV, Richard Katherine T., Hern Kenneth, .

Insider Roster

Insider Dir Off 10% Shares Owned
Richard Katherine T. Director
X 40,850
Nierenberg David Director
X 1,706,862
Marietta Matthew B EVP Finance & Corp Development
X 94,975
Walton H. Richard Chief Accounting Officer
X 276,547
CHISHOLM JOHN Chairman, President and CEO, Director
X X 1,178,696
SNIVELY JOSHUA A EVP Operations
X 455,516
Hern Kenneth Director
X 122,880
Brown Ted D Director
X 76,649
Adams Michelle M Director
X 56,512
McGuire LV Director
X 158,216
Cooper L Melvin Director
X 137,868
Bodnar Robert C Executive Vice President
X 76,955
REEVES STEVEN A Exec. VP, Operations
X 295,095
REILAND JOHN Director
X 51,165
Hardy Carla S. Director
X 416,633
Schmitz Robert M. Chief Financial Officer
X 52,617

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-07-11 4 Richard Katherine T. A D 40,850 40,850
2018-06-01 4 Nierenberg David A D 40,323 1,665,913
2018-05-16 4 SNIVELY JOSHUA A P D 3.4073 4,450 455,516 1,552,080
2018-05-15 4 SNIVELY JOSHUA A P D 3.4035 5,766 451,066 1,535,203
2018-05-15 4 CHISHOLM JOHN P D 3.4093 33,600 1,178,696 4,018,528
2018-05-16 4 Walton H. Richard P D 3.3842 20,000 276,547 935,890
2018-05-15 4 Marietta Matthew B P D 3.3558 6,850 94,975 318,717
2018-04-27 4 Cooper L Melvin A D 3.74 33,423 137,868
2018-04-27 4 McGuire LV A D 3.74 33,423 158,216
2018-04-27 4 Adams Michelle M A D 3.74 33,423 56,512
2018-04-27 4 Brown Ted D A D 3.74 33,423 76,649
2018-04-27 4 Hern Kenneth A D 3.74 33,423 122,880
2018-03-16 4 SNIVELY JOSHUA A A D 6.13 49,000 445,300
2018-03-16 4 SNIVELY JOSHUA A A D 6.13 75,000 396,300
2018-03-16 4 Marietta Matthew B A D 6.13 25,125 88,125
2018-03-16 4 Marietta Matthew B A D 6.13 60,000 63,000
2018-03-16 4 Walton H. Richard A D 6.13 25,313 256,547
2018-03-16 4 Walton H. Richard A D 6.13 30,000 231,234
2018-03-16 4 CHISHOLM JOHN A D 6.13 96,750 1,145,096
2018-01-16 4 CHISHOLM JOHN A D 5.85 170,834 1,048,346
2018-01-16 4 SNIVELY JOSHUA A A D 5.85 44,904 321,300
2018-01-16 4 Walton H. Richard A D 5.85 36,667 201,234
2017-12-31 4 SNIVELY JOSHUA A F D 4.66 -9,373 276,396
2017-12-31 4 CHISHOLM JOHN F D 4.66 -24,181 877,512
2017-09-21 4 Bodnar Robert C F D 5.29 -5,823 76,955
2017-09-13 4 Hern Kenneth P D 5.455 1,000 89,457 487,988
2017-06-30 4 REEVES STEVEN A F D 8.94 -43,828 295,095
2017-05-18 4 Hern Kenneth F D 9.72 -7,716 88,457
2017-05-18 4 Hern Kenneth M D 8.29 9,047 96,173
2017-05-18 4 REILAND JOHN F D 9.72 -7,716 51,165
2017-05-18 4 REILAND JOHN M D 8.29 9,047 58,881
2017-05-18 4 McGuire LV F D 9.72 -7,716 124,793
2017-05-18 4 McGuire LV M D 8.29 9,047 132,509
2017-05-18 4 Cooper L Melvin F D 9.72 -7,716 104,445
2017-05-18 4 Cooper L Melvin M D 8.29 9,047 112,161
2017-04-21 4 Hardy Carla S. A D 11.75 10,639 416,633
2017-04-21 4 Brown Ted D A D 11.75 10,639 43,226
2017-04-21 4 Cooper L Melvin A D 11.75 10,639 103,114
2017-04-21 4 Adams Michelle M A D 11.75 10,639 23,089
2017-04-21 4 REILAND JOHN A D 11.75 10,639 49,834
2017-04-21 4 McGuire LV A D 11.75 10,639 123,462
2017-04-21 4 Hern Kenneth A D 11.75 10,639 87,126
2017-04-06 4 CHISHOLM JOHN F D 12.59 -321,522 902,116
2017-04-06 4 CHISHOLM JOHN M D 9.19 400,000 1,223,638
2017-04-04 4 REEVES STEVEN A F D 12.49 -169,325 341,565
2017-04-04 4 REEVES STEVEN A M D 9.19 200,000 510,890
2017-02-13 4 Schmitz Robert M. D D -18,976 52,617
2017-02-24 4 REEVES STEVEN A A D 68,333 310,890
2017-03-15 4 Hern Kenneth S D 11.60 -15,000 76,487 887,249
2017-02-22 4 REILAND JOHN S D 12.726 -15,000 39,195 498,796
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Flotek Industries Is Making Adjustments For A Solid Recovery

2018-08-31 seekingalpha
Flotek Industries (FTK) provides chemistry and services that are used in the oil and gas industries and in the consumer and industrial markets. In 2018, so far, Flotek Industries' stock price has dipped by 53%, while VanEck Vectors Oil Services ETF (OIH) declined 4%. OIH represents the oilfield equipment & services (or OFS) industry. FTK has some near-term challenges from the operational perspective as well as some structural headwinds. (13-1)

Stocks To Watch: Alibaba, Target And Energy Plays To Center Stage

2018-08-18 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (150-3)

Are Options Traders Betting on a Big Move in Flotek Industries (FTK) Stock?

2018-08-16 zacks
Investors in Flotek Industries, Inc. (FTK - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 17, 2018 $3.00 Put had some of the highest implied volatility of all equity options today. (12-0)

Flotek Industries, Inc. (FTK) CEO John Chisholm on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha
Good morning, and welcome to the Flotek Industries Incorporated Second Quarter 2018 Earnings Conference Call. [Operator Instructions]. This conference is being recorded. (12-0)